Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Brooklyn ImmunoTherapeutics initiated with a Buy at Maxim » 08:03
10/06/21
10/06
08:03
10/06/21
08:03
BTX

Brooklyn ImmunoTherapeutics

$8.97 /

+ (+0.00%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy initiated coverage of Brooklyn ImmunoTherapeutics with a Buy rating and $20 price target. The analyst cites the company having "two potentially high value platforms in oncology" with its IL-2 asset, IRX-2, in an ongoing P2b trial in head and neck cancer along with an expansion to additional Phase 2 programs based on outcomes from investigator-sponsored trials. McCarthy adds that Brooklyn ImmunoTherapeutics' acquisition of Novellus Therapeutics positions its with an mRNA/GE platform that could facilitate the development of engineered cell therapies that are "highly targeted, more effective, and safer".

ShowHide Related Items >><<
BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

10/06/21 Maxim
Brooklyn ImmunoTherapeutics initiated with a Buy at Maxim
BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

Initiation
Brooklyn ImmunoTherapeutics initiated with a Buy at Maxim » 07:47
10/06/21
10/06
07:47
10/06/21
07:47
BTX

Brooklyn ImmunoTherapeutics

$8.97 /

+ (+0.00%)

Maxim analyst Jason…

Maxim analyst Jason McCarthy initiated coverage of Brooklyn ImmunoTherapeutics with a Buy rating and $20 price target.

ShowHide Related Items >><<
BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

BTX Brooklyn ImmunoTherapeutics
$8.97 /

+ (+0.00%)

Over a month ago
Hot Stocks
Brooklyn ImmunoTherapeutics appoints Roger Sidhu as CMO » 10:11
09/22/21
09/22
10:11
09/22/21
10:11
BTX

Brooklyn ImmunoTherapeutics

$9.68 /

+0.05 (+0.52%)

, GILD

Gilead

$71.21 /

-0.52 (-0.72%)

Brooklyn…

Brooklyn ImmunoTherapeutics (BTX) announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma, a subsidiary of Gilead Sciences (GILD).

ShowHide Related Items >><<
GILD Gilead
$71.21 /

-0.52 (-0.72%)

BTX Brooklyn ImmunoTherapeutics
$9.68 /

+0.05 (+0.52%)

BTX Brooklyn ImmunoTherapeutics
$9.68 /

+0.05 (+0.52%)

GILD Gilead
$71.21 /

-0.52 (-0.72%)

09/09/21 RBC Capital
Biden drug reform plan has 'few new concepts or specifics,' says RBC Capital
07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
GILD Gilead
$71.21 /

-0.52 (-0.72%)

BTX Brooklyn ImmunoTherapeutics
$9.68 /

+0.05 (+0.52%)

GILD Gilead
$71.21 /

-0.52 (-0.72%)

GILD Gilead
$71.21 /

-0.52 (-0.72%)

BTX Brooklyn ImmunoTherapeutics
$9.68 /

+0.05 (+0.52%)

GILD Gilead
$71.21 /

-0.52 (-0.72%)

BTX Brooklyn ImmunoTherapeutics
$9.68 /

+0.05 (+0.52%)

Hot Stocks
Brooklyn ImmunoTherapeutics provides highlights from shareholder update call » 08:32
09/21/21
09/21
08:32
09/21/21
08:32
BTX

Brooklyn ImmunoTherapeutics

$9.93 /

-2.07 (-17.25%)

Brooklyn…

Brooklyn ImmunoTherapeutics provided highlights from a Shareholder Update Call conducted on September 20, 2021 by President and Chief Executive Officer Howard Federoff, M.D., Ph.D., with guest contributor Matt Angel, Ph.D., Factor Bioscience's Co-founder and Chief Executive Officer. Highlights of the call included: Brooklyn is building on its license from Factor Bioscience, its acquisition of Novellus Therapeutics and its placement of its R&D facility at 1035 Cambridge Street alongside Factor Bioscience. Brooklyn plans to use iMSCs - mesenchymal stem cells derived from induced pluripotent stem cells, or iPSCs - to address allogeneic bone marrow transplants that have functioned poorly or have failed to address the cancer associated with the procedure. Brooklyn plans to apply its gene editing products to solid tumors. Brooklyn outlined its proposed approach for gene editing products to treat monogenic disorders by targeting the liver, brain and eye. Dr. Federoff described Brooklyn's expected approach to autologous iPSCs with gene editing to address problems such as sickle cell disease. Based on intellectual property licensed from Factor Bioscience, Brooklyn's highly efficient mRNA strategy is designed to preclude cellular innate immune responses and, when coupled with a tunable nanolipid delivery system such as the ToRNAdo system, could allow Brooklyn to address clinical problems that have not been addressable before.

ShowHide Related Items >><<
BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

Conference/Events
Brooklyn ImmunoTherapeutics to hold a conference call » 16:15
09/20/21
09/20
16:15
09/20/21
16:15
BTX

Brooklyn ImmunoTherapeutics

$9.93 /

-2.07 (-17.25%)

Management conducts a…

Management conducts a shareholder update conference call on the Company's mRNA cell-engineering platform, which is being developed to leverage patented mRNA and gene editing technology on September 20 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

BTX Brooklyn ImmunoTherapeutics
$9.93 /

-2.07 (-17.25%)

Conference/Events
Brooklyn ImmunoTherapeutics to hold a conference call » 11:11
09/20/21
09/20
11:11
09/20/21
11:11
BTX

Brooklyn ImmunoTherapeutics

$10.89 /

-1.11 (-9.25%)

Management conducts a…

Management conducts a shareholder update conference call on the Company's mRNA cell-engineering platform, which is being developed to leverage patented mRNA and gene editing technology on September 20 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
BTX Brooklyn ImmunoTherapeutics
$10.89 /

-1.11 (-9.25%)

BTX Brooklyn ImmunoTherapeutics
$10.89 /

-1.11 (-9.25%)

BTX Brooklyn ImmunoTherapeutics
$10.89 /

-1.11 (-9.25%)

BTX Brooklyn ImmunoTherapeutics
$10.89 /

-1.11 (-9.25%)

Hot Stocks
Brooklyn ImmunoTherapeutics to participate in opening of mRNA cleanroom facility » 08:43
09/09/21
09/09
08:43
09/09/21
08:43
BTX

Brooklyn ImmunoTherapeutics

$11.57 /

-0.25 (-2.12%)

Brooklyn…

Brooklyn ImmunoTherapeutics announced that Chief Executive Officer and President Howard J. Federoff, M.D., Ph.D., will participate in the grand opening and ribbon cutting ceremony for its mRNA Cleanroom facility shared with Factor Bioscience in Cambridge, Mass. The new facility, which Brooklyn anticipates using to develop new products for patients with cancer, sickle cell, ARDS and other diseases using state-of-the-art technology mRNA, gene editing, and iMSCs, is located at the Factor Bioscience headquarters at 1035 Cambridge Street in Cambridge, Massachusetts. The facility was custom designed for Brooklyn's needs in cell engineering, with capacity sufficient to support both near- and long-term clinical development. It was designed with modular flexibility to accommodate various cell and nucleic acid processes, and to comply with U.S. performance criteria. The co-location with Factor's R&D and process development lab space and internal manufacturing capacity will provide Brooklyn with production flexibility and efficiency. The facility provides Brooklyn with access to 2,700 square feet of contiguous lab space that will support the creation of seven R&D jobs.

ShowHide Related Items >><<
BTX Brooklyn ImmunoTherapeutics
$11.57 /

-0.25 (-2.12%)

BTX Brooklyn ImmunoTherapeutics
$11.57 /

-0.25 (-2.12%)

BTX Brooklyn ImmunoTherapeutics
$11.57 /

-0.25 (-2.12%)

BTX Brooklyn ImmunoTherapeutics
$11.57 /

-0.25 (-2.12%)

Hot Stocks
Brooklyn ImmunoTherapeutics provides highlights from shareholder update call » 08:34
08/20/21
08/20
08:34
08/20/21
08:34
BTX

Brooklyn ImmunoTherapeutics

$8.85 /

-1.05 (-10.61%)

Brooklyn…

Brooklyn ImmunoTherapeutics provided highlights from a Shareholder Update Call conducted by President and Chief Executive Officer Howard Federoff, M.D., Ph.D. on August 19, 2021. Highlights included: Brooklyn is well underway in integrating Novellus into its operations; Strategic planning and alignment across all pipeline programs is proceeding; Brooklyn is focusing on an initial set of mesenchymal stem cell products, derived from induced pluripotent stem cells, for which it also intends to apply its gene editing technology; The Phase 2 INSPIRE study of lead compound IRX-2 remains on schedule for a topline data readout in the first half of 2022 and Brooklyn continues to collect data; Additional clinical stage development programs for IRX-2 are continuing both for monotherapies and in combination with checkpoint inhibitors; Brooklyn is exploring the use of iPSC with the ability to add additional properties via gene editing; Brooklyn is developing in vivo gene editing to address monogenic diseases; and current cash position of approximately $25 million is expected to enable personnel recruitment, growth and strategic investment

ShowHide Related Items >><<
BTX Brooklyn ImmunoTherapeutics
$8.85 /

-1.05 (-10.61%)

BTX Brooklyn ImmunoTherapeutics
$8.85 /

-1.05 (-10.61%)

BTX Brooklyn ImmunoTherapeutics
$8.85 /

-1.05 (-10.61%)

BTX Brooklyn ImmunoTherapeutics
$8.85 /

-1.05 (-10.61%)

Conference/Events
SNN Network to hold a virtual event » 09:32
08/18/21
08/18
09:32
08/18/21
09:32
STAF

Staffing 360 Solutions

$2.25 /

-0.37 (-14.12%)

, VNRX

VolitionRx

$3.02 /

-0.16 (-5.03%)

, BLGO

BioLargo

/

+

, BCTX

BriaCell

$5.28 /

-0.015 (-0.28%)

, PYR

PyroGenesis

$3.86 /

+0.11 (+2.93%)

, DLTNF

Delta 9 Cannabis

/

+

, KSPN

Kaspien Holdings

$21.00 /

+0.5 (+2.44%)

, BTX

Brooklyn ImmunoTherapeutics

$10.62 /

-0.01 (-0.09%)

, GOVX

GeoVax Labs

$3.76 /

-0.33 (-8.07%)

, ISDR

Issuer Direct

$27.74 /

-0.26 (-0.93%)

, PRPH

ProPhase Labs

$5.39 /

-0.3 (-5.27%)

, VEV

Vicinity Motor

$5.26 /

-0.205 (-3.75%)

, SOLO

ElectraMeccanica

$3.36 /

-0.1 (-2.89%)

, PTPI

Petros Pharmaceuticals

$2.51 /

-0.185 (-6.86%)

, BITF

Bitfarms

$5.41 /

-0.995 (-15.55%)

SNN Network Summer…

SNN Network Summer Virtual Event 2021 to be held on August 17-19. Webcast Link

ShowHide Related Items >><<
VNRX VolitionRx
$3.02 /

-0.16 (-5.03%)

VEV Vicinity Motor
$5.26 /

-0.205 (-3.75%)

STAF Staffing 360 Solutions
$2.25 /

-0.37 (-14.12%)

SOLO ElectraMeccanica
$3.36 /

-0.1 (-2.89%)

PYR PyroGenesis
$3.86 /

+0.11 (+2.93%)

PTPI Petros Pharmaceuticals
$2.51 /

-0.185 (-6.86%)

PRPH ProPhase Labs
$5.39 /

-0.3 (-5.27%)

KSPN Kaspien Holdings
$21.00 /

+0.5 (+2.44%)

GOVX GeoVax Labs
$3.76 /

-0.33 (-8.07%)

DLTNF Delta 9 Cannabis
/

+

BTX Brooklyn ImmunoTherapeutics
$10.62 /

-0.01 (-0.09%)

BITF Bitfarms
$5.41 /

-0.995 (-15.55%)

BCTX BriaCell
$5.28 /

-0.015 (-0.28%)

STAF Staffing 360 Solutions
$2.25 /

-0.37 (-14.12%)

07/23/21 Greenridge
Staffing 360 Solutions price target lowered to $8.50 from $15 at Greenridge
05/19/21 Greenridge
Staffing 360 Solutions price target lowered to $2.50 from $3.50 at Greenridge
VNRX VolitionRx
$3.02 /

-0.16 (-5.03%)

03/09/21 Cantor Fitzgerald
VolitionRx initiated with an Overweight at Cantor Fitzgerald
11/13/20 Oppenheimer
VolitionRx vet test could be bridge with human tests delayed, says Oppenheimer
BLGO BioLargo
/

+

BCTX BriaCell
$5.28 /

-0.015 (-0.28%)

PYR PyroGenesis
$3.86 /

+0.11 (+2.93%)

DLTNF Delta 9 Cannabis
/

+

KSPN Kaspien Holdings
$21.00 /

+0.5 (+2.44%)

03/24/21 Aegis
Kaspien Holdings initiated with a Buy at Aegis
BTX Brooklyn ImmunoTherapeutics
$10.62 /

-0.01 (-0.09%)

GOVX GeoVax Labs
$3.76 /

-0.33 (-8.07%)

11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
11/19/20 Maxim
GeoVax Labs initiated with a Buy at Maxim
ISDR Issuer Direct
$27.74 /

-0.26 (-0.93%)

08/25/20 Northland
Issuer Direct price target raised to $18 from $16 at Northland
PRPH ProPhase Labs
$5.39 /

-0.3 (-5.27%)

01/20/21 Dawson James
ProPhase Labs initiated with a Buy at Dawson James
VEV Vicinity Motor
$5.26 /

-0.205 (-3.75%)

SOLO ElectraMeccanica
$3.36 /

-0.1 (-2.89%)

12/16/20 Stifel
ElectraMeccanica initiated with a Buy at Stifel
12/16/20 Colliers
ElectraMeccanica initiated with a Buy at Colliers
11/23/20 Roth Capital
ElectraMeccanica price target raised to $12.25 from $7.50 at Roth Capital
10/29/20 Roth Capital
Roth reiterates Buy rating on ElectraMeccanica after first deliveries from China
PTPI Petros Pharmaceuticals
$2.51 /

-0.185 (-6.86%)

BITF Bitfarms
$5.41 /

-0.995 (-15.55%)

VNRX VolitionRx
$3.02 /

-0.16 (-5.03%)

STAF Staffing 360 Solutions
$2.25 /

-0.37 (-14.12%)

SOLO ElectraMeccanica
$3.36 /

-0.1 (-2.89%)

PYR PyroGenesis
$3.86 /

+0.11 (+2.93%)

PRPH ProPhase Labs
$5.39 /

-0.3 (-5.27%)

KSPN Kaspien Holdings
$21.00 /

+0.5 (+2.44%)

DLTNF Delta 9 Cannabis
/

+

BTX Brooklyn ImmunoTherapeutics
$10.62 /

-0.01 (-0.09%)

  • 16
    Mar
  • 24
    Feb
  • 10
    Feb
  • 10
    Feb
  • 24
    Dec
  • 25
    Sep
PYR PyroGenesis
$3.86 /

+0.11 (+2.93%)

STAF Staffing 360 Solutions
$2.25 /

-0.37 (-14.12%)

PRPH ProPhase Labs
$5.39 /

-0.3 (-5.27%)

BTX Brooklyn ImmunoTherapeutics
$10.62 /

-0.01 (-0.09%)

SOLO ElectraMeccanica
$3.36 /

-0.1 (-2.89%)

PYR PyroGenesis
$3.86 /

+0.11 (+2.93%)

PTPI Petros Pharmaceuticals
$2.51 /

-0.185 (-6.86%)

BTX Brooklyn ImmunoTherapeutics
$10.62 /

-0.01 (-0.09%)

BITF Bitfarms
$5.41 /

-0.995 (-15.55%)

On The Fly
Fly Intel: Pre-market Movers » 08:57
08/16/21
08/16
08:57
08/16/21
08:57
CVAC

CureVac

$58.84 /

-0.72 (-1.21%)

, ADMA

ADMA Biologics

$1.48 /

-0.025 (-1.66%)

, RCKT

Rocket Pharmaceuticals

$29.94 /

-0.82 (-2.67%)

, OTLY

Oatly Group

$16.88 /

-0.1 (-0.59%)

, TSHA

Taysha Gene Therapies

$17.31 /

-0.21 (-1.20%)

, PSFE

Paysafe

$10.21 /

-0.675 (-6.20%)

, DOYU

DouYu

$3.45 /

+0.015 (+0.44%)

, VET

Vermilion Energy

$7.09 /

-0.21 (-2.88%)

, BTX

Brooklyn ImmunoTherapeutics

$11.16 /

-0.57 (-4.86%)

, UWMC

UWM Holdings

$7.87 /

+0.415 (+5.57%)

, TSLA

Tesla

$717.22 /

-4.99 (-0.69%)

Check out this morning's…

ShowHide Related Items >><<
UWMC UWM Holdings
$7.87 /

+0.415 (+5.57%)

TSLA Tesla
$717.22 /

-4.99 (-0.69%)

TSHA Taysha Gene Therapies
$17.31 /

-0.21 (-1.20%)

RCKT Rocket Pharmaceuticals
$29.94 /

-0.82 (-2.67%)

PSFE Paysafe
$10.21 /

-0.675 (-6.20%)

OTLY Oatly Group
$16.88 /

-0.1 (-0.59%)

DOYU DouYu
$3.45 /

+0.015 (+0.44%)

CVAC CureVac
$58.84 /

-0.72 (-1.21%)

BTX Brooklyn ImmunoTherapeutics
$11.16 /

-0.57 (-4.86%)

ADMA ADMA Biologics
$1.48 /

-0.025 (-1.66%)

CVAC CureVac
$58.84 /

-0.72 (-1.21%)

07/01/21 Berenberg
CureVac COVID vaccine data may be enough for EU approval, says Berenberg
06/30/21
CureVac announces COVID vaccine candidate demonstrates 48% efficacy
06/30/21 B. Riley
B. Riley downgraded Vaxart to Neutral on 'riskier development path'
06/21/21 Barclays
Arcturus Therapeutics downgraded to Underweight from Equal Weight at Barclays
ADMA ADMA Biologics
$1.48 /

-0.025 (-1.66%)

07/06/21 H.C. Wainwright
ADMA Biologics price target lowered to $7 from $10 at H.C. Wainwright
10/01/20 Raymond James
ADMA Biologics price target raised to $9 from $7 at Raymond James
09/30/20 Jefferies
ADMA Biologics shares 'in arbitrage territory,' says Jefferies
RCKT Rocket Pharmaceuticals
$29.94 /

-0.82 (-2.67%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
OTLY Oatly Group
$16.88 /

-0.1 (-0.59%)

07/15/21 Piper Sandler
Piper view on Oatly unchanged after short report, keeps $30 target
06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Nordea
Oatly Group initiated with a Hold at Nordea
06/14/21
Fly Intel: Top five analyst initiations
TSHA Taysha Gene Therapies
$17.31 /

-0.21 (-1.20%)

07/15/21 Needham
Taysha Gene Therapies initiated with a Buy at Needham
07/09/21 Chardan
Taysha Gene Therapies coverage transferred at Chardan
06/24/21 Truist
Truist starts Taysha Gene Therapies at Buy on potential de-risking events
06/24/21 Truist
Taysha Gene Therapies initiated with a Buy at Truist
PSFE Paysafe
$10.21 /

-0.675 (-6.20%)

08/12/21 BofA
Paysafe started with a Buy at BofA amid rapidly growing iGaming market
08/12/21 BofA
Paysafe initiated with a Buy at BofA
06/28/21 Cowen
Paysafe initiated with an Outperform at Cowen
06/24/21 Susquehanna
Paysafe continues to position itself well, says Susquehanna
DOYU DouYu
$3.45 /

+0.015 (+0.44%)

07/13/21 China Renaissance
DouYu assumed with a Hold at China Renaissance
04/23/21 86 Research
DouYu upgraded to Buy from Hold at 86 Research
11/05/20 China Renaissance
DouYu downgraded to Hold from Buy at China Renaissance
11/05/20 China Renaissance
Huya downgraded to Hold from Buy at China Renaissance
VET Vermilion Energy
$7.09 /

-0.21 (-2.88%)

07/29/21 Desjardins
Vermilion Energy assumed with a Buy at Desjardins
07/15/21 Scotiabank
Vermilion Energy price target raised to C$12.50 from C$11.50 at Scotiabank
07/14/21 CIBC
Vermilion Energy price target raised to C$12.50 from C$10 at CIBC
06/28/21 Stifel
Vermilion Energy price target raised to C$12.25 from C$10.25 at Stifel
BTX Brooklyn ImmunoTherapeutics
$11.16 /

-0.57 (-4.86%)

UWMC UWM Holdings
$7.87 /

+0.415 (+5.57%)

07/12/21 Jefferies
UWM Holdings price target lowered to $8 from $9.50 at Jefferies
07/12/21 Morgan Stanley
UWM Holdings initiated with an Equal Weight at Morgan Stanley
07/09/21 Barclays
UWM Holdings price target raised to $9 from $8 at Barclays
07/01/21 Keefe Bruyette
Keefe Bruyette starts UWM Holdings at Market Perform on profitability concern
TSLA Tesla
$717.22 /

-4.99 (-0.69%)

08/10/21 GLJ Research
Tesla China sales figures for July 'nothing short of bad,' says GLJ Research
08/09/21
Fly Intel: Top five analyst upgrades
08/09/21 Jefferies
Tesla upgraded to Buy on accelerating earnings leverage at Jefferies
08/09/21 Jefferies
Tesla upgraded to Buy from Hold at Jefferies
VET Vermilion Energy
$7.09 /

-0.21 (-2.88%)

UWMC UWM Holdings
$7.87 /

+0.415 (+5.57%)

TSLA Tesla
$717.22 /

-4.99 (-0.69%)

TSHA Taysha Gene Therapies
$17.31 /

-0.21 (-1.20%)

RCKT Rocket Pharmaceuticals
$29.94 /

-0.82 (-2.67%)

PSFE Paysafe
$10.21 /

-0.675 (-6.20%)

OTLY Oatly Group
$16.88 /

-0.1 (-0.59%)

DOYU DouYu
$3.45 /

+0.015 (+0.44%)

BTX Brooklyn ImmunoTherapeutics
$11.16 /

-0.57 (-4.86%)

ADMA ADMA Biologics
$1.48 /

-0.025 (-1.66%)

  • 20
    May
  • 28
    Jan
  • 10
    Dec
  • 24
    Sep
TSLA Tesla
$717.22 /

-4.99 (-0.69%)

OTLY Oatly Group
$16.88 /

-0.1 (-0.59%)

DOYU DouYu
$3.45 /

+0.015 (+0.44%)

CVAC CureVac
$58.84 /

-0.72 (-1.21%)

VET Vermilion Energy
$7.09 /

-0.21 (-2.88%)

TSLA Tesla
$717.22 /

-4.99 (-0.69%)

RCKT Rocket Pharmaceuticals
$29.94 /

-0.82 (-2.67%)

PSFE Paysafe
$10.21 /

-0.675 (-6.20%)

OTLY Oatly Group
$16.88 /

-0.1 (-0.59%)

DOYU DouYu
$3.45 /

+0.015 (+0.44%)

CVAC CureVac
$58.84 /

-0.72 (-1.21%)

BTX Brooklyn ImmunoTherapeutics
$11.16 /

-0.57 (-4.86%)

ADMA ADMA Biologics
$1.48 /

-0.025 (-1.66%)

VET Vermilion Energy
$7.09 /

-0.21 (-2.88%)

UWMC UWM Holdings
$7.87 /

+0.415 (+5.57%)

TSLA Tesla
$717.22 /

-4.99 (-0.69%)

PSFE Paysafe
$10.21 /

-0.675 (-6.20%)

OTLY Oatly Group
$16.88 /

-0.1 (-0.59%)

DOYU DouYu
$3.45 /

+0.015 (+0.44%)

CVAC CureVac
$58.84 /

-0.72 (-1.21%)

BTX Brooklyn ImmunoTherapeutics
$11.16 /

-0.57 (-4.86%)

ADMA ADMA Biologics
$1.48 /

-0.025 (-1.66%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.